FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to use of soluble polypeptide of CCR6 receptor in treating of interstitial pulmonary disease and/or lung cancer. Polypeptide containing CCLVYTSWQI, which consists of amino acid sequence, which has at least 90 % identity with respect to sequence according to SEQ ID NO: 9. Its fragment is also obtained, containing at least 12 amino acids of above sequence, including CCLVYTSWQI.
EFFECT: invention allows preparing polypeptide capable to inhibit CCL18 induced step-down regulation of CCR6 expression.
1 cl, 33 dwg, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
| COMPOSITIONS AND METHODS OF TREATING CANCER | 2016 |
|
RU2729396C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| ISOLATED POLYPEPTIDE AND USING IT FOR TREATING MALIGNANT DISEASE AND STIMULATING IMMUNE SYSTEM, PHARMACEUTICAL COMPOSITION CONTAINING SUCH POLYPEPTIDE AND METHOD OF TREATING CANCER | 2008 |
|
RU2518236C2 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| POLYPEPTIDES AND POLYNUCLEOTIDES AND THEIR USE FOR TREATMENT OF IMMUNE DISORDERS AND CANCER | 2012 |
|
RU2623161C2 |
| NEW ISOFORMS OF VASCULAR ENDOTHELIAL CELL GROWTH INHIBITOR | 2002 |
|
RU2316591C2 |
| ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
| NEW LIGAND OF CYTOKINE RECEPTOR ZCYTOR17 | 2003 |
|
RU2490276C2 |
